US › Healthcare

NanoViricides Inc (NNVC)

US · Healthcare · Biotechnology

$1.52-1.94%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-2.0M

Profit YoY

+10.3%

EPS

$-0.09

EPS estimate

$-0.08

EPS came in at -0.09 against a street estimate of -0.08 — a miss of 12.5%.

Key statistics

Market cap

$38.8M

Forward P/E

0.0

P/B

4.23

Book value

$0.42

EPS (TTM)

$-0.44

52-week high

$2.23

52-week low

$0.85

50-day MA

$1.51

200-day MA

$1.30

Beta

1.67

Analyst view

Analysts rate NanoViricides Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $6.00.

Shareholding

Insiders

2.36%

Institutions

7.51%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for NanoViricides Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.